| Maryland | 98-1141883 | | | --- | --- | --- | | (State or other jurisdiction | (IRS Employer | | | of incorporation or organization) | Identification No.) | | | 666 Burrard Street | | | | Suite 3210 | | | | Vancouver, BC | | | | V6C 2X8 | | | | (Address of principal executive offices) (Zip Code) | | | | Registrant's telephone number, including area code: (604) 806-3366 | | | | Securities registered pursuant to Section 12(b) of the Act: | | | | Title of Each Class Trading Symbol(s) | Name of each Exchange ...

Exhibit 99.1 City Office REIT Reports First Quarter 2025 Results VANCOUVER—May 2, 2025 —City Office REIT, Inc. (NYSE: CIO) (the "Company," "City Office," "we" or "our") today announced its results for the quarter ended March 31, 2025. First Quarter Highlights Highlights Subsequent to Quarter End • Entered into an agreement with an affiliate of Property Markets Group ("PMG") to redevelop a portion of the Company's City Center property in St. Petersburg, Florida into a planned 49-story residential condominium ...

Core Viewpoint - Central Iron Ore Limited has commenced the next phase of resource expansion drilling at the British King Project in Western Australia, with a total of 78 Reverse Circulation drill holes planned over a 9-week campaign [1][5]. Drilling Update - The 2025 drilling program is structured in two phases, with Phase 1 focusing on resource expansion and Phase 2 aimed at targeted infill drilling to upgrade the inferred resource to indicated status [4]. - Phase 1 involves 78 RC drill holes totaling 10,601 meters, designed to extend the geological model of the British King deposit in all directions [5]. Project Location - The British King Project is situated on the M37/30 Mining Tenement, approximately 320 kilometers northwest of Kalgoorlie and 60 kilometers east of Leinster in Western Australia [6].

Investors interested in REIT and Equity Trust - Other stocks are likely familiar with City Office REIT (CIO) and EastGroup Properties (EGP) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores h ...

Core Insights - Tevogen Bio Holdings Inc. is focused on immunotherapy and artificial intelligence, with recent presentations highlighting its AI-driven technology for T cell therapies [1][3] - The company aims to develop off-the-shelf, genetically unmodified precision T cell therapies to address significant unmet medical needs in infectious diseases and cancers [4][5] Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company utilizing CD8+ cytotoxic T lymphocytes for therapeutic development [4] - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and multiple pending patents related to artificial intelligence [4] Recent Events - Mittul Mehta, the Chief Information Officer, presented at the AI x Bio Philly event, discussing Tevogen.AI's proprietary technology that accelerates the discovery and development of precision T cell therapies [1][3][2] - The event gathered innovators and investors to explore the impact of AI on biotechnology, showcasing the convergence of these fields [2]

Core Insights - Cybersecurity is the top concern for 41% of Chief Information Officers (CIOs), yet 77% are increasing security budgets, 68% are expanding cloud infrastructure, and 67% are accelerating AI capabilities [1][6] - CIOs are blending security and innovation to create competitive advantages, embedding resilience into digital foundations while deploying advanced technologies [2][5] Cybersecurity and Budgeting - 77% of organizations plan to increase cybersecurity budgets in 2025, indicating a strong focus on enhancing security measures [6] - The relationship with the Chief Operating Officer (COO) is identified as the most important C-suite partnership outside IT [6] AI Adoption - Only 37% of CIOs view generative AI as a valuable solution for specific applications today, while 33% are uncertain about its business impact [4] - Despite the cautious outlook, 33% of organizations are actively exploring AI technologies, and 27% are already implementing them [4] Regional Variations - In the Netherlands, 67% of tech leaders are reducing carbon footprints through technology while maintaining security [5] - 86% of CIOs in Italy are increasing cybersecurity investments while being enthusiastic about AI adoption [5] - In France, 38% of CIOs report that advocating for adequate budget resources is their greatest challenge, higher than the global average of 25% [5] Organizational Maturity - The study identifies five organizational maturity categories, with "Front Runners" (24%) characterized by customer-centric technology strategies and strong alignment with business objectives, while "Snoozers" (14%) show skepticism toward AI [5]

Core Insights - Robert Half has been recognized as one of Fortune's 2025 America's Most Innovative Companies and has won the 2025 CIO 100 Award, highlighting its commitment to innovation and technology solutions [1][2] - The recognition is based on an extensive evaluation of product, process, and company culture, involving insights from over 45,000 U.S. employees across more than 3,000 companies [2] - The company emphasizes its investment in AI and technology to enhance recruitment processes and improve customer experiences [3][4] Company Achievements - Robert Half is the only company in its industry to receive the aforementioned accolades, showcasing its unique position in the market [1] - The company has also received a Stevie Award for 'Best Artificial Intelligence/Machine Learning Solution' for its AI capabilities that benefit clients, candidates, and employees [4] - In the past year, Robert Half has been named one of Fortune's Most Admired Companies and one of the 100 Best Companies to Work For [5] Technology and Innovation - The company utilizes AI-powered tools that leverage advanced machine learning and proprietary data to create real-time candidate shortlists and optimize client outreach [3] - Robert Half's technology initiatives significantly enhance its ability to connect top talent with challenging roles, thereby improving service delivery to customers [4] - The focus on innovation is embedded in the company's culture, as stated by its CEO, emphasizing the importance of providing a world-class experience for customers and empowering employees [3]

Core Insights - Investors primarily use price-to-earnings (P/E) and price-to-sales (P/S) ratios for stock valuation, while the price-to-book (P/B) ratio is also a useful metric for identifying undervalued stocks with growth potential [1][2] Group 1: Understanding P/B Ratio - The P/B ratio is calculated as market capitalization divided by book value of equity, helping to identify low-priced stocks with high growth prospects [2] - A P/B ratio of less than one indicates that a stock is trading below its book value, suggesting it may be undervalued and a good buy [5] - Conversely, a P/B ratio greater than one suggests that a stock may be overvalued [5][6] Group 2: Limitations of P/B Ratio - A P/B ratio of less than one can also indicate weak or negative returns on assets, or that assets are overstated, which may warrant caution [7] - The P/B ratio is particularly relevant for industries with tangible assets, such as finance and manufacturing, but may be misleading for companies with high R&D expenditures or significant debt [8] Group 3: Screening Parameters for Investment - Stocks with a P/B ratio lower than the industry median may have room for price appreciation [11] - A lower P/S ratio compared to the industry median makes a stock more attractive, as it indicates better value for each dollar of sales [11] - A P/E ratio lower than the industry median is also considered favorable for investment decisions [12] Group 4: Selected Low P/B Stocks - JD.com has a Zacks Rank of 1 and a projected 3-5 year EPS growth rate of 32.3% [15][16] - City Office REIT holds a Zacks Rank of 2 with a projected EPS growth rate of 6.0% [16] - Fresenius Medical Care has a Zacks Rank of 1 and a projected EPS growth rate of 11.9% [17] - Itron, with a Zacks Rank of 2, has a projected EPS growth rate of 29.0% [18] - EnerSys has a Zacks Rank of 2 and a projected EPS growth rate of 18.0% [19][20]

Core Viewpoint - Central Iron Ore Limited has filed a National Instrument 43-101 Technical Report for the British King Gold Project in Western Australia, indicating significant progress in resource estimation and project readiness [1][2]. Group 1: Technical Report Details - The Technical Report, prepared by Andrew Bewsher MAIG, has an effective date of March 20, 2025, and is compliant with National Instrument 43-101 standards [2]. - The report concludes that the 2024 drilling programs have enhanced geological and grade confidence, resulting in an Indicated and Inferred Mineral Resource Estimate (MRE) of 263,000 tonnes at a grade of 4.51 g/t Au, totaling approximately 38,100 ounces of gold [3]. - Metallurgical tests indicate that the mineralization is suitable for standard carbon in leach processing, achieving a recovery rate exceeding 90% [3]. Group 2: Project Development Steps - The Technical Report outlines the need for a heritage survey, hydrogeology assessment, geotechnical assessment, and a mining study to advance the project towards submitting a mining proposal to DEMIRS Western Australia [4]. - Successful completion of these assessments will position the British King deposit for mining readiness [4]. Group 3: Company Overview - Central Iron Ore Limited is an Australian resource exploration and development company focused on creating shareholder value through the exploration and development of its properties in Australia [6].

Core Insights - Tevogen Bio is leveraging AI to enhance precision medicine and operational efficiencies in the biotech sector [2][3] - The company is focused on developing off-the-shelf, genetically unmodified precision T cell therapies to address significant unmet medical needs [5][6] Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company utilizing CD8+ cytotoxic T lymphocytes for treating infectious diseases and cancers [5] - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and multiple pending patents related to AI [5][6] Industry Context - The AI discussion panel highlighted the transformative impact of AI across finance, biotech, and legal sectors, emphasizing the need for tailored approaches to address unique industry challenges [2][3] - The event featured industry leaders discussing the latest advancements in AI and its applications in enhancing operational efficiencies [4]